$435M: Series C for Epigenetic Reprogramming Trial 

NewLimit closed a $435 million Series C financing. The company plans to launch its first human clinical trial next year, testing a liver cell-reprogramming therapy. NewLimit's approach uses epigenetic reprogramming — altering DNA markings that govern which genes a cell uses — to restore liver cells to a more youthful state. The company said its candidate has shown the ability to accelerate liver recovery from injury and improve tolerance of dietary and alcohol-related stress in preclinical models.

$180M: Series A for Oral Medicine for Inflammatory Diseases 

cAMPfield Therapeutics has launched with $180 million in a Series A round. The money will help advance cAMPfield’s lead candidate, prifemilast (HY1999/HPP737), for the treatment of inflammatory bowel diseases. The company is launching a global phase 2b trial for moderate-to-severe ulcerative colitis and a global phase 2 for Crohn’s disease. PDE4 inhibition is a well-established approach in certain inflammatory diseases. The enzyme, expressed in various immune-related cells, degrades cyclic adenosine monophosphate (cAMP), which is involved in regulating inflammatory pathways. Blocking PDE4 therefore increases intracellular cAMP, which in turn could reduce pro-inflammatory cytokines while promoting anti-inflammatory cytokines.

$125M: Series B for Ultrasound-Mediated Nonviral Genetic Medicines 

SonoThera closed an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline across multiple organ systems and further scale its proprietary platform technologies designed to enable safe, targeted, and repeatable delivery of genetic medicines. The financing follows significant preclinical progress demonstrating targeted delivery across multiple tissues and successful delivery of both large DNA and RNA payloads, underscoring strong investor conviction in SonoThera’s platform and pipeline.

$93M: Series A for Retinal Disease Bispecific Antibody 

Memento Medicines completed a $93 million Series A financing round. Memento has also entered into an exclusive license agreement with MabTics and Curacle to obtain worldwide rights to MMT-205. MMT-205, previously known as MT-103, is a bispecific antibody that activates Tie2 and inhibits VEGF, two clinically validated targets that play a central role in the pathogenesis of retinal and vascular diseases. Under the terms of the license agreement, MabTics and Curacle have received upfront consideration comprising cash payments and equity in Memento and are also eligible for additional development, regulatory, and commercial milestones and tiered royalties on net sales.

$86.6M: Series B for First-in-Class Breast Cancer and Colorectal Cancer ADCs 

Ona closed an oversubscribed $86.6 million Series B financing. The proceeds will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class antibody-drug conjugate initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need.

$65M: Series C for Immunological and Inflammatory Disorders Treatments 

Triveni Bio announced a $65 million Series C financing round. Proceeds will allow the company to extend the scope and rigor of clinical development of TRIV-573, including an atopic dermatitis phase 2 clinical proof-of-concept study expected to initiate later this year. TRIV-573 is a half-life extended, next-generation bispecific engineered to address the underlying cause of atopic dermatitis by simultaneously inhibiting KLK5/7 — validated as central drivers of skin barrier dysfunction — and the Th2 cytokine IL-13.

$52M: Series D for Early Cancer Detection 

ClearNote Health announced the close of $52 million in Series D financing. Proceeds will support continued commercial expansion, clinical study execution, product development, and broader global access to ClearNote Health’s portfolio of Avantect early cancer detection tests and Virtuoso epigenomic drug development platform. Aventect is a highly sensitive, noninvasive pancreatic and ovarian test that may identify cancers in high-risk patient populations earlier than conventional approaches, when patients may be more likely to benefit from treatment. The Virtuoso epigenomics platform builds on the latest advances in artificial intelligence and bioinformatics to measure active biological differences between cancer and healthy cells in a blood sample.

$46M: Series A for Next-Gen Migraine Therapies 

Vedana emerged from stealth with $46 million in Series A financing. Proceeds from the financing will be used to advance Vedana’s portfolio of internally discovered, potentially best-in-class, subcutaneously delivered antibodies targeting clinically validated pathways for migraine prevention. Vedana’s lead program is the next-generation anti-PACAP antibody, and its second program targets both PACAP and CGRP. While targeting PACAP alone provides a novel approach beyond currently approved drugs, Vedana’s bispecific antibody targeting both PACAP and CGRP could potentially deliver additional efficacy for patients who do not achieve relief with monotherapies.

$40M: Financing for Non-Viral Delivery of Full-Length Dystrophin 

Spot Biosystems emerged from stealth with $40 million in venture financing, landmark preclinical research published in Nature Biomedical Engineering, and an ongoing first-in-human clinical trial with early results showing potential for successful translation to patients with Duchenne muscular dystrophy (DMD). The peer-reviewed study demonstrated for the first time that full-length dystrophin, whose absence in the body causes DMD, could be delivered non-virally to skeletal muscle. In DMD knockout mice, EV-delivered dystrophin mRNA produced sustained protein expression and significantly improved muscle strength, endurance, and motor function. In non-human primates, repeated intravenous dosing resulted in sustained dystrophin expression without liver, kidney, or cardiac toxicity.

$34M: Financing for Medicines That Slow Aging 

Gero announced a total equity funding of $34 million. Gero combines longitudinal human data, AI, and a physics-based aging framework for therapeutic target identification and drug design. Gero's approach was born from a crucial but underappreciated observation: nature has already achieved dramatic slowing of aging and extremely long healthy life in several complex mammals. Gero’s thesis is that aging and age-related disease onset follow quantifiable physical laws that can be read in human data and turned into medicines. Gero trained AI world models of human health on approximately 10 million curated longitudinal medical records, selected from more than 100 million records and integrated with molecular, omics, and genetic data. By pairing a validated discovery engine with non-dilutive partnership revenue, Gero intends to advance a portfolio of both disease-modifying and aging-slowing programs in parallel, with the proceeds supporting preclinical development of its pipeline and continued expansion of pharmaceutical partnerships.

$30M: Series A for Duchenne-Associated Cardiomyopathy Treatment 

Secretome closed a $30 million Series A financing. The funds will support company operations and the continued development of Secretome’s pipeline, including STM-01, a neonatal cardiac progenitor cells-derived therapy in development for Duchenne muscular dystrophy-associated cardiomyopathy and other rare forms of cardiomyopathy secondary to neuromuscular disease. Secretome expects to use the proceeds to advance STM-01 toward pivotal phase 2 and phase 3 development in Duchenne muscular dystrophy, an indication with few disease-modifying therapeutic options.

$20M: Series A for AI-Designed Cell Therapies 

Waypoint Bio closed a $20 million Series A financing round. The funds will help advance Waypoint’s WAY-103, the company’s lead program for gastric and pancreatic solid tumors, into an investigator-initiated trial beginning in late 2026. WAY-103 has demonstrated greater than 15-fold improved potency in animal models compared to multiple clinical benchmarks, alongside reduced on-target/off-tumor toxicity. Additionally, Waypoint will expand its AI and spatial biology platform and the buildout of its clinical development capabilities.

$9M: Series A for Cell Engineering Platform  

Portal Biotechnologies has raised $9 million in a Series A round. Pharma partners have started using the company’s cell engineering platform to screen harder-to-deliver molecules, generate training data for AI models and explore point-of-care cell therapy manufacturing. Portal’s platform uses mechanoporation to deliver materials such as RNA, gene editors, probes and antibodies into cells that can be difficult to work with. Portal is also adding AI data generation to its offerings, where existing delivery tools can limit the types of cells, cargos and experiments researchers can use.

$8.8M: Seed Financing for Next-Gen Neuroplastogen 

Psilera announced the successful closing of an oversubscribed $8.8 million Series Seed extension funding round. The company intends to use the funds to advance its lead clinical asset, PSIL-006, towards first-in-human trials in 2027. PSIL-006 is a first-in-class neuroplastogen designed to harness the therapeutic benefits of traditional psychedelic compounds while minimizing hallucinogenic effects and cardiovascular risks.

$8M: Series A for Accelerating Life Science Labs 

Scispot announced an $8 million Series A. Modern labs are under pressure to move faster, but much of their work is still split across disconnected instruments, spreadsheets, electronic lab notebooks, lab information management systems, scientific data systems, reports, dashboards, and manual handoffs. This slows experiments, decisions, and the path from lab work to real-world use. Scispot gives labs one operating layer for that work. Permissions, audit trails, sample lineage, approvals, and human review are built in. The platform captures context as work happens, traces each step, automates routine digital work, and turns lab activity into structured, traceable data that teams and AI agents can use.